Clinical Genomics Appoints Mark Boyle President, In Vitro Diagnostics

BRIDGEWATER, N.J., Dec. 21, 2016 -- Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced the appointment of Mark Boyle as President, In Vitro Diagnostics (IVD).

“Mark’s appointment comes at a critical time for our company,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “As we planned for and recently announced the launch of Colvera™, our two-gene test for CRC recurrence monitoring, we recognized the importance of placing a strong leader at the helm of our successful FIT-based screening franchise. With a career spanning more than two decades in the global IVD and life sciences markets, Mark brings a wealth of highly relevant experience that make him uniquely qualified to manage and grow our global FIT testing business.”

Mr. Boyle brings 26 years of commercial experience at leading global IVD and life science companies to his new role at Clinical Genomics. Prior to joining the Company, he served as Vice President at QIAGEN Inc. for nearly five years where he successfully led the company’s global business portfolio in tuberculosis management and helped achieve more than $100 million in revenues. Previously, he was President of Cellestis Inc., where he successfully launched and led the adoption of a screening test for tuberculosis. As a member of the Cellestis executive team, Mr. Boyle played a critical role in the company reaching profitability and was instrumental to its acquisition and successful integration into QIAGEN. He also served as General Manager for the U.K. subsidiary of Diagnostic Systems Laboratories Inc., an IVD manufacturer; and held sales and marketing positions with two Australian biotech start-ups. He holds a B.Sc. in biochemistry and microbiology, and a graduate certificate in management from the University of Adelaide, Australia.

About Colorectal Cancer
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but only approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 40 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.

About Clinical Genomics
Clinical Genomics is a privately held biotechnology company committed to reducing the impact of colorectal cancer (CRC) through early detection of disease and clinically actionable, evidence-driven recurrence monitoring tools. With a broad intellectual property portfolio consisting of more than 20 patents, Clinical Genomics, via its wholly-owned subsidiary Enterix Inc., currently offers the user-friendly, patient-preferred CRC screening InSure^® FIT™ assay, a fecal immunochemical test that detects blood in the stool. InSure is also marketed as a lab-based test in Australia and other countries (ColoVantage Home). Building on an established history in the field of CRC screening and diagnosis, Clinical Genomics developed Colvera, a blood-based circulating tumor DNA (ctDNA) test for colorectal cancer based on methylated DNA from two genes, BCAT1 and/or IKZF1.

Clinical Genomics has offices and laboratories in Bridgewater and Edison, New Jersey and Sydney, Australia, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

For more information, please visit www.colveratest.com and www.clinicalgenomics.com.

Media Contact:
Danielle Lewis, Lazar Partners
(212) 843-0211 or (917) 907-4239
[email protected]